TP53 and cancer: Fifteen of the 21 NGS-analyzed cases displayed co-mutations in other cancer-relevant genes (Table 2), with TP53-mutations being the most represented (n=10, 67%, subdivided in 7 missense mutations, 1 intronic substitution, 2 previously unreported frameshift deletions).